About Us
AnTaimmu BioMed Co., Ltd., founded in Apr. 2018 is a new drug discovery company focusing on developing novel therapeutic antibodies and protein drugs. The headquarter locates in Hsinchu Science Park of Taiwan since Jul. 2020. Our primary goal is to develop novel immunotherapy antibody drugs for cancer with enhanced efficiency and fewer side effects. Based on our bioinformatics and protein science technologies, we have constructed human synthetic antibody libraries, naive antibody libraries, and antibody libraries from immunized animals for screening specific monoclonal antibodies of cancer target molecules.
As a biologics drug development company, we will develop our drug until an early phase of the clinical trial and then cooperate with an international pharmaceutical company to complete the clinical drug development. We value humanity and are committed to improving human health. The final goal for AnTaimmu is to become the leading provider of antibody therapy.
EN 
ZH_TW